

wherein W is optionally substituted aryl; optionally substituted C₅-C₇ cycloalkyl; -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl and optionally substituted aryl; OR' where R' is optionally substituted aryl; optionally substituted C₃-C₇ cycloalkyl; or optionally substituted C₁-C₆ alkyl; provided that R¹ and R² are not both hydrogen;

Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-;


X is O or S; and

Y is optionally substituted C₂-C₃ alkylene; provided that W is not OR' when Z is imino or -CH₂NH-;

or a pharmaceutically acceptable salt or ester thereof.

46. A method according to claim 45 wherein the disease of the central nervous system is selected from dementia, mood disturbances, degenerative conditions such as stroke or aging, ischaemia, CNS trauma, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

47. A method of the treatment or prevention of glaucoma comprising administering an effective amount of a compound of formula II



al cont.
wherein W is optionally substituted aryl; optionally substituted C₅-C₇ cycloalkyl; -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl and optionally substituted aryl; OR' where R' is optionally substituted aryl; optionally substituted C₃-C₇ cycloalkyl; or optionally substituted C₁-C₆ alkyl; provided that R¹ and R² are not both hydrogen;

Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-;

X is O or S; and

Y is optionally substituted C₂-C₃ alkylene; provided that W is not OR' when Z is imino or -CH₂NH-; and

with the further provisos that

a) when Y is CH₂CH₂, X is O and Z is imino then

(i) if W is CHR¹R² and R¹ is H then R² is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; 3-nitrophenyl; 3- or 4-

RESPONSE TO RESTRICTION REQUIREMENT
Application No. 09/530,807

methylphenyl; 2- or 4-bromomethyl phenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6-dimethylphenyl; and

(ii) if W is CHR^1R^2 and R^1 is CH_3 or cyclopropyl then R^2 is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and

b) when Y is $(\text{CH}_2)_{2-4}$, X is O or S, Z is imino and W is CHR^1R^2 , then


(i) if R^1 is CF_3 , CF_2CF_3 or $\text{CF}_2\text{CF}_2\text{CF}_3$ then R^2 is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and

(ii) if R^1 is optionally substituted cyclopropyl, R^2 is not H, alkyl or optionally substituted cyclopropyl;

or a pharmaceutically acceptable ester or salt thereof, to a subject in need thereof.

48. A method for the treatment of diseases of the central nervous system, cardiovascular system, or the kidney, or diseases associated with abnormal adrenal gland secretions, or in the

treatment or prevention of hyperglycaemia, glaucoma, peptic ulcer or to produce analgesia which comprises administering an effective amount of a compound of formula II



wherein W is optionally substituted aryl; optionally substituted C₅-C₇ cycloalkyl; -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl and optionally substituted aryl; OR' where R' is optionally substituted aryl; optionally substituted C₃-C₇ cycloalkyl; or optionally substituted C₁-C₆ alkyl; provided that R¹ and R² are not both hydrogen;

Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-;

X is O or S; and

Y is optionally substituted C₂-C₃ alkylene; provided that W is not OR' when Z is imino or -CH₂NH-; and

with the further provisos that

a) when Y is CH₂CH₂, X is O and Z is imino then

(i) W is not unsubstituted or 2-mono-, 2,2-di, 2,5-di, 2,6-di or 2,4,6-tri C₁₋₃ alkyl substituted cyclohexyl or 2-mono- or 2,5,-di C₁₋₃ alkyl substituted cyclopentyl or 2-C₁₋₃ alkyl substituted cycloheptyl; and

RESPONSE TO RESTRICTION REQUIREMENT
Application No. 09/530,807

(ii) if W is CHR^1R^2 and R^1 is H then R^2 is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethylphenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6-dimethylphenyl; and

(iii) if W is CHR^1R^2 and R^1 is CH_3 or cyclopropyl then R^1 is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and

*Al-
Conceded* b) when Y is $(\text{CH}_2)_{2-4}$, X is O or S, Z is imino and W is CHR^1R^2 , then

(i) if R^1 is CF_3 , CF_2CF_3 or $\text{CF}_2\text{CF}_2\text{CF}_3$ then R^2 is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and

(ii) if R^1 is optionally substituted cyclopropyl, R^2 is not H, alkyl or optionally substituted cyclopropyl;

or a pharmaceutically acceptable ester or salt thereof, to a subject in need thereof.